A frequent benign breast tumor, fibroadenoma mammae (FAM), has extra stromal and epithelial components in the breast tissue. Despite not being fatal, FAM increases breast cancer risk, highlighting the necessity to recognize it. Estrogen and progesterone levels during menstruation, pregnancy, and lactation may alter FAM development. Therefore, this study examines FAM risk variables in adult women at South Tangerang Regional General Hospital, Indonesia. Adult women in General Hospital of South Tangerang City, Indonesia were studied using a case-control design with 85 cases and 85 controls. South Tangerang General Hospital recruited volunteers between December 2023 and January 2024 using purposeful sampling. FAM patients with a history of therapy were cases, while Eye Clinic patients without FAM were controls. Viral diseases, major cardiovascular problems in the past three years, and unstable weight were excluded. Multivariate analyses employed multiple logistic regression, while univariate and bivariate analyses used percentages and chi-square test. Fibroadenoma mammae (FAM) prevalence in adult women at South Tangerang General Hospital is highly correlated with age, age of menarche, family history, hormonal contraceptive use, and nutritional status. Abnormal nutrition was the largest risk factor for FAM in hospitalized adult women (aOR = 8.678, p < 0.000). The study stresses the link between nutritional state and FAM, with abnormal nutritional status increasing risk. This shows how diet and nutrition affect FAM sensitivity. To reduce FAM prevalence, demographic, genetic, hormonal, and lifestyle factors must be understood and addressed due to their complex interaction. Dietary strategies that promote healthy eating may reduce FAM risk.

1. Kopkash K, Yao K. The surgeon’s guide to fibroadenomas. Annals of Breast Surgery. 2020; 4: 25-25. doi: 10.21037/abs-20-100

2. Ramala SR, Chandak S, Chandak MS, Annareddy S. A Comprehensive Review of Breast Fibroadenoma: Correlating Clinical and Pathological Findings. Cureus. 2023;15(12): 1-13.

3. Shi L, Chang L, Wang J, et al. Juvenile fibroadenoma of breast: A case report. International Journal of Radiation Research. 2023; 21(4): 841-843. doi: 10.61186/ijrr.21.4.841

4. Ajmal M, Khan M, Van Fossen K. Breast Fibroadenoma. Available online: https://www.ncbi.nlm.nih.gov/books/NBK535345/ (accessed on 20 April 2024).

5. Yarso K, Putra MD, Bellynda M, et al. Video-Assisted Breast Surgery (VABS) and Vacuum-Assisted Breast Biopsy (VABB) for Fibroadenoma Mammae on Patients’ Satisfaction: A Preliminary Study. Asian Pacific Journal of Cancer Prevention. 2021; 22(11): 3615-3621. doi: 10.31557/apjcp.2021.22.11.3615

6. Dupont WD, Page DL, Parl FF, et al. Long-Term Risk of Breast Cancer in Women with Fibroadenoma. New England Journal of Medicine. 1994; 331(1): 10-15. doi: 10.1056/nejm199407073310103

7. Kementerian Kesehatan Republik Indonesia. Hasil Utama Riset Kesehatan Dasar 2018. Available online: http://www.depkes.go.id/resources/download/info-terkini/hasil-riskesdas-2018.pdf (accessed on 20 April 2024).

8. Kementerian Kesehatan Republik Indonesia. Data Program Deteksi Dini Sadanis dan IVA. Kementerian Kesehatan Republik Indonesia, Jakarta; 2018.

9. Fitri AE, Khambri D, Afriwardi. Risk factors analysis of fibroadenoma mammae in adolescent girls in 2021. Sci Midwifery. 2022; 10(2): 1788-1792.

10. Hutchings HA, Remesh A. An evaluation of the readability and visual appearance of online patient resources for fibroadenoma. Vall-llosera Camps M, ed. PLOS ONE. 2022; 17(11): e0277823. doi: 10.1371/journal.pone.0277823

11. Scott RJ. Familial Adenomatous Polyposis (FAP) and Other Polyposis Syndromes. Hereditary Cancer in Clinical Practice. 2003; 1(1): 19. doi: 10.1186/1897-4287-1-1-19

12. Pai S. The spectrum of benign breast diseases among females: A 6-year histopathological study. Indian Journal of Pathology and Oncology. 2019; 6(4): 561-567. doi: 10.18231/j.ijpo.2019.110

13. Jensen EV, Jordan VC. The Estrogen Receptor: A Model for Molecular Medicine. Clin Cancer Res. 2003; 9(6): 1980-1989.

14. Horwitz KB, Mcguire WL. Specific progesterone receptors in human breast cancer. Steroids. 1975; 25(4): 497-505.

15. Dixon JM. Cystic disease and fibroadenoma of the breast: Natural history and relation to breast cancer risk. British Medical Bulletin. 1991; 47(2): 258-271. doi: 10.1093/oxfordjournals.bmb.a072468

16. Lee M. Breast fibroadenomas in adolescents: current perspectives. Adolesc Health Med Ther. 2015; 6: 159-163.

17. Bidgoli SA, Eftekhari T. Role of Exogenous and Endogenous Sources of Estrogen on the Incidence of Breast Fibroadenoma: Case-control Study in Iran. Asian Pacific J Cancer Prev. 2011; 12: 1289-1293.

18. Li J, Humphreys K, Ho PJ, et al. Family History, Reproductive, and Lifestyle Risk Factors for Fibroadenoma and Breast Cancer. JNCI Cancer Spectr. 2018; 2(3): pky051. doi: 10.1093/jncics/pky051

19. Yu H, Rohan TE, Cook MG, et al. Risk Factors for Fibroadenoma: A Case-Control Study in Australia. American Journal of Epidemiology. 1992; 135(3): 247-258. doi: 10.1093/oxfordjournals.aje.a116278

20. Lacroix AE, Gondal H, Shumway KR, Langaker MD. Physiology, Menarche. Treasure Island (FL): StatPearls Publishing; 2024.

21. Kay JE, Cardona B, Rudel RA, et al. Chemical Effects on Breast Development, Function, and Cancer Risk: Existing Knowledge and New Opportunities. Current Environmental Health Reports. 2022; 9: 535-562. doi: 10.1007/s40572-022-00376-2

22. Canelón SP, Boland MR. A Systematic Literature Review of Factors Affecting the Timing of Menarche: The Potential for Climate Change to Impact Women’s Health. International Journal of Environmental Research and Public Health. 2020; 17(5): 1703. doi: 10.3390/ijerph17051703

23. Michels KB, Keller K, Pereira A, et al. Association between indicators of systemic inflammation biomarkers during puberty with breast density and onset of menarche. Breast Cancer Research. 2020; 22(1). doi: 10.1186/s13058-020-01338-y

24. Dall GV, Britt KL. Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk. Frontiers in Oncology. 2017; 7. doi: 10.3389/fonc.2017.00110

25. Yoo JH. Effects of early menarche on physical and psychosocial health problems in adolescent girls and adult women. Korean Journal of Pediatrics. 2016; 59(9): 355. doi: 10.3345/kjp.2016.59.9.355

26. Pandit P, Murkey SP, Agarwal A, et al. Understanding Fibroadenoma of the Breast: A Comprehensive Review of Pre-operative and Post-operative Clinicopathological Correlations. Cureus. 2023; 15(12): 1-13.

27. Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & Diseases. 2018; 5(2): 77-106. doi: 10.1016/j.gendis.2018.05.001

28. Bertelsen L, Mellemkjaer L, Balslev E, et al. Benign Breast Disease among First-Degree Relatives of Young Breast Cancer Patients. American Journal of Epidemiology. 2008; 168(3): 261-267. doi: 10.1093/aje/kwn133

29. Berkey CS, Tamimi RM, Rosner B, et al. Young women with family history of breast cancer and their risk factors for benign breast disease. Cancer. 2011; 118(11): 2796-2803. doi: 10.1002/cncr.26519

30. Sun SX, Bostanci Z, Kass RB, et al. Breast Physiology: Normal and Abnormal Development and Function. In: The Breast, 5th ed. Elsevier Inc.; 2018. pp. 37–56. doi: 10.1016/b978-0-323-35955-9.00003-9

31. Walsh MF, Cadoo K, Salo-Mullen EE, et al. Genetic Factors: Hereditary Cancer Predisposition Syndromes. In: Abeloff’s Clinical Oncology, 6th ed. Elsevier Inc.; 2020. pp. 180-208. doi: 10.1016/B978-0-323-47674-4.00013-X

32. Eng C, Hampel H, Chapelle A de la. Genetic Testing for Cancer Predisposition. Annual Review of Medicine. 2001; 52(1): 371-400. doi: 10.1146/annurev.med.52.1.371

33. Teal S, Edelman A. Contraception Selection, Effectiveness, and Adverse Effects. JAMA. 2021; 326(24): 2507. doi: 10.1001/jama.2021.21392

34. Atashgaran V, Wrin J, Barry SC, et al. Dissecting the Biology of Menstrual Cycle-Associated Breast Cancer Risk. Frontiers in Oncology. 2016; 6. doi: 10.3389/fonc.2016.00267

35. Lovett JL, Chima MA, Wexler JK, et al. Oral contraceptives cause evolutionarily novel increases in hormone exposure. Evolution, Medicine, and Public Health. 2017; 2017(1): 97-108. doi: 10.1093/emph/eox009

36. Hunt JT, Kamat R, Yao M, et al. Effect of contraceptive hormonal therapy on mammographic breast density: A longitudinal cohort study. Clinical Imaging. 2023; 97: 62-67. doi: 10.1016/j.clinimag.2023.03.001

37. Schindler AE. Non-Contraceptive Benefits of Oral Hormonal Contraceptives. International Journal of Endocrinology and Metabolism. 2012; 11(1). doi: 10.5812/ijem.4158

38. Tejwani PL, Nerkar H, Dhar A, et al. Regression of Fibroadenomas with Centchroman: A Randomized Controlled Trial. Indian J Surg. 2015;77(Suppl 2): 484-489. doi: 10.1007/s12262-013-0886-4

39. Crain DA, Janssen SJ, Edwards TM, et al. Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertility and Sterility. 2008; 90(4): 911-940. doi: 10.1016/j.fertnstert.2008.08.067

40. Pu X, Chen D. Targeting Adipokines in Obesity-Related Tumors. Frontiers in Oncology. 2021; 11. doi: 10.3389/fonc.2021.685923

41. Danforth DN. The Role of Chronic Inflammation in the Development of Breast Cancer. Cancers. 2021; 13(15): 3918. doi: 10.3390/cancers13153918

42. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2007; 371(9612): 569-578.